Aige Eye Hospital Secures $40 Million Series B Funding Led by CDH Investments with Advancina as Exclusive Financial Advisor

VCBeat (WeChat: vcbeat) has learned that Aier Eye Hospital Group (“Aier Eye”) recently announced it had secured $40 million in Series B financing from CDH Investments. This round follows Aier Eye’s Series A investment in 2015 from OrbiMed Advisors. China Renaissance Capital served as the exclusive financial advisor to Aier Eye in this transaction.

Aier Eye Hospital is the first Sino-foreign joint venture eye care chain group in Central China, and one of the largest professional eye care chain medical institutions in the region. Through years of dedicated operations and an unwavering commitment to medical excellence, Aier Eye Hospital has established strong brand influence and a solid market reputation in Hubei Province and throughout Central China.

According to available records, Wuhan Aier Eye Hospital was established on August 8, 2003. It is a tertiary-level specialized eye hospital integrating medical care, teaching, scientific research, and blindness prevention. As a Sino-foreign joint venture ophthalmic medical group, it is also a designated hospital for medical insurance in Wuhan City, Hubei Province, and for nationwide cross-regional medical insurance settlements.

The hospital boasts 15,000 square meters of operational space and employs over 500 staff members. It features ten specialized departments: Cataract, Fundus Diseases, Refractive Surgery, Strabismus and Pediatric Ophthalmology, Lacrimal Duct Diseases, Corneal and Ocular Surface Diseases, Orbital Diseases, Glaucoma, Oculoplastic Surgery, and Medical Optometry and Glasses Fitting. These departments provide comprehensive, professional, and systematic diagnostic and therapeutic services to a wide range of patients with eye conditions.

Aier Eye Hospital has always adhered to the mission of “ensuring everyone’s right to clear vision” and upheld the business philosophy that “professionalism is paramount.” Leveraging a robust team of experts and advanced diagnostic and therapeutic equipment, it provides high-quality, comprehensive ophthalmic medical services to patients of all ages.

Aier Eye Hospital has cumulatively provided ophthalmic medical services to over 3 million patient visits, performed more than 200,000 surgeries, and maintained an annual growth rate of over 40%, securing a leading position in the Hubei region.

Aier Eye Hospital has already established multiple large-scale eye hospitals in Wuhan and other core cities across Hubei Province. Moving forward, it will continue to anchor its operations in Hubei and Central China, while gradually expanding into South China, East China, and Southwest China, with the goal of completing a network of 30 premium hospitals by 2022.

Regarding this transaction, Mr. Ye Ronghua, Chairman of Aier Eye Hospital Group, stated: “We sincerely appreciate CDH Investments and OrbiMed for their trust and support in Aier Eye Hospital Group. This strategic alliance with CDH will leverage our combined strengths to further enhance Aier’s medical management and service standards, accelerate the implementation of our premium hospital development strategy, improve patient experience, and earn greater public recognition.”

Mr. Wang Lin, Founding Partner of CDH Investments, stated, “As a renowned ophthalmic hospital in Hubei Province, Aier Eye Hospital has achieved remarkable success over years of development. Through this collaboration, we aim to leverage the complementary strengths of capital and industry expertise to achieve win-win outcomes, support Aier Eye Hospital’s strategic growth, and help establish it as a leading brand in China’s ophthalmology sector.”

Meanwhile, Mr. Wang Guowei, Partner at OrbiMed, stated, “In 2015, OrbiMed was pleased to see Aier Eye Hospital’s localized brand influence in Wuhan and entered into a partnership with it. By welcoming CDH Investments to join our strategic alliance and building a broader platform for collaboration, we aim to jointly foster a more vibrant industry landscape in the field of ophthalmic healthcare.”

Following this round of financing,Aier Eye Hospital will accelerate the group's networked layout., and further enhance the service capabilities of existing hospitals, while making new attempts in innovative business models that balance the decentralization of medical resources with healthcare quality, striving to become a leading premium ophthalmology chain brand in China.